AstraZeneca Pharmaceuticals LP
NEWS
Idea Pharma’s annual index reveals key drivers and metrics for large companies. AstraZeneca and Pfizer remain in the top positions this year for invention and innovation, respectively.
The Oncologic Drugs Advisory Committee voted 11–1 supporting Merck’s and AstraZeneca’s PARP inhibitor for metastatic castration-resistant prostate cancer patients with BRCA mutations.
Merck and AstraZeneca are seeking broad approval for Lynparza in mCRPC regardless of BRCA status.
Eplontersen halted ATTRv-PN disease progression and improved quality of life through 66 weeks. The drug has a PDUFA date of Dec. 22, 2023.
Roche, AstraZeneca, Moderna, Merck and Affimed presented new data in liver cancer, lung cancer, melanoma and lymphoma.
AstraZeneca’s Imfinzi and Lynparza met primary endpoint markers in the Phase III DUO-O trial in advanced high-grade epithelial ovarian cancer, according to data released Wednesday.
AstraZeneca reported positive data from both the Phase III ADAURA trial studying Tagrisso (osimertinib) and the Phase III AEGEAN studying Imfinzi (durvalumab) in NSCLC patients.
On Rare Disease Day, Feburary 28, AstraZeneca announced the creation of the Alexion, AstraZeneca Rare Disease Development Hub in Toronto, Ontario.
The FDA accepted the BLA for and granted Pfizer’s maternal RSV vaccine candidate priority review.
JOBS
IN THE PRESS